21ьз╕ C

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

News Provided by PR Newswire2025-07-30

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

[30-July-2025]

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search

Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com

BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experience and freeing up more time for patient care.

Laboratory testing plays a critical role in healthcare, informing nearly 70% of clinical decisions and often serving as the first step in diagnosing and managing patient conditions. Yet research shows providers spend more than three hours a day on responsibilities including documentation and test ordering—time that could be spent with patients. According to a recent American Medical Association (AMA) survey, 57% of physicians view addressing administrative burden through automation as the greatest opportunity for AI in healthcare.

"Clinicians are under increasing pressure to do more with less," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Test Finder is designed to ease that burden by providing a faster, more intuitive way to navigate complex test menus, conduct research and identify the right tests, so clinicians can focus on what matters most: their patients."

Key Features of Labcorp's Test Finder
Now available on Labcorp.com, Test Finder was developed using Amazon Bedrock and large language model (LLM) technology. The tool enables providers to ask questions or describe conditions in plain language and receive a detailed list of suggested tests and descriptions based on their input. Additional benefits include:

Access to thousands of lab tests across key therapeutic areas, including oncology, women's health, neurology, autoimmune disease and more
Faster, more efficient navigation that reduces time spent on test selection
Available 24/7 on Labcorp.com

"Labcorp's AI implementation underscores the transformative power of responsible generative AI in healthcare, setting a new industry standard for clinical workflow optimization," said Dr. Rowland Illing, global chief medical officer at AWS. "By leveraging AWS' enterprise-grade AI infrastructure and HIPAA-compliant security controls, Labcorp is revolutionizing how healthcare providers access comprehensive diagnostic information, enabling faster decisions that can directly impact patient care outcomes."

"Test Finder is a powerful example of how we're using technology to simplify complexity," said Bola Oyegunwa, Ph.D., Labcorp's chief information and technology officer. "By integrating generative AI, we're not only improving the provider experience, we're laying the foundation for smarter, more connected healthcare solutions that scale with the needs of our customers."

Labcorp anticipates sharing additional updates and announcements related to Test Finder in the coming weeks. For more information, visit www.labcorp.com.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.